Relapsed testicular germ cell tumours (GCTs) might be cured with salvage chemotherapy. Accepted salvage treatment is conventional-dose chemotherapy (CDCT) or high-dose chemotherapy (HDCT). HDCT with peripheral blood stem cell transplant might produce a higher number of durable responses than CDCT. We discuss studies reporting on outcomes of salvage HDCT in relapsed GCTs. The most reproducible results were achieved with HDCT with two cycles of etoposide and carboplatin or three cycles of the paclitaxel, ifosfamide, carboplatin and etoposide regime. Using these two regimens, sustained cure rates of 50–66% were reported in phase I, phase II and retrospective studies published in the past two decades. Cure rates in patients with cisplatin-resistant disease are between 30% and 45%. Two phase III randomized studies were conducted with certain limitations and were unsuccessful in showing a survival benefit of HDCT. Thus, salvage treatment remains a controversial topic. Salvage HDCT with peripheral blood stem cell transplant and CDCT are two recommended treatment options for relapsed GCTs. Consistently reported cure rates from phase I, phase II and large retrospective studies support the use of HDCT in the hands of an experienced team of oncologists.
Established salvage treatment for relapsed testicular germ cell tumours is conventional-dose chemotherapy or high-dose chemotherapy (HDCT), which might cure 20–60% of patients.
Consistently reported cure rates from phase I and II studies and large retrospective cohorts suggest that HDCT with two cycles of etoposide and carboplatin or three cycles of paclitaxel, ifosfamide, carboplatin and etoposide might be superior to conventional-dose chemotherapy.
HDCT with peripheral blood stem cell transplant is a standard approach in several high-volume institutions.
HDCT with peripheral blood stem cell transplant should be performed by teams of experienced oncologists.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Einhorn, L. H. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol. 8, 1777–1781 (1990).
Hanna, N. H. & Einhorn, L. H. Testicular cancer — discoveries and updates. N. Engl. J. Med. 371, 2005–2016 (2014).
Chovanec, M., Hanna, N., Cary, K. C., Einhorn, L. & Albany, C. Management of stage I testicular germ cell tumours. Nat. Rev. Urol. 13, 663–673 (2016).
Beyer, J. et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J. Clin. Oncol. 39, 1553–1562 (2021).
Gillessen, S. et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J. Clin. Oncol. 39, 1563–1574 (2021).
Motzer, R. J. et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 67, 1305–1310 (1991).
Mardiak, J. et al. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. Neoplasma 52, 497–501 (2005).
Motzer, R. J. Paclitaxel (Taxol) combination therapy for resistant germ cell tumors. Semin. Oncol. 27, 33–35 (2000).
Adra, N. et al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J. Clin. Oncol. 35, 1096–1102 (2017).
Feldman, D. R. et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J. Clin. Oncol. 28, 1706–1713 (2010).
Lorch, A. et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J. Clin. Oncol. 29, 2178–2184 (2011).
Li, M. C., Whitmore, W. F. Jr., Golbey, R. & Grabstald, H. Effects of combined drug therapy on metastatic cancer of the testis. JAMA 174, 1291–1299 (1960).
Hanna, N. & Einhorn, L. H. Testicular cancer — discoveries and updates. N. Engl. J. Med. 371, 2342 (2014).
Rosenberg, B., Vancamp, L. & Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698–699 (1965).
Higby, D. J., Wallace, H. J. Jr, Albert, D. J. & Holland, J. F. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer 33, 1219–1215 (1974).
Einhorn, L. H. & Donohue, J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87, 293–298 (1977).
Einhorn, L. H. & Williams, S. D. Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer 46, 1339–1344 (1980).
Einhorn, L. H., Williams, S. D., Troner, M., Birch, R. & Greco, F. A. The role of maintenance therapy in disseminated testicular cancer. N. Engl. J. Med. 305, 727–731 (1981).
Stoter, G. et al. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J. Clin. Oncol. 4, 1199–1206 (1986).
Williams, S. D. et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316, 1435–1440 (1987).
Powis, G. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug. Metab. Rev. 14, 1145–1163 (1983).
Bleyer, W. A. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41, 36–51 (1978).
Creasey, W. A. et al. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Res. 36, 216–221 (1976).
Hillcoat, B. L., McCulloch, P. B., Figueredo, A. T., Ehsan, M. H. & Rosenfeld, J. M. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br. J. Cancer 38, 719–724 (1978).
Ozols, R. F. et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J. Clin. Oncol. 6, 1031–1040 (1988).
Miller, R. P., Tadagavadi, R. K., Ramesh, G. & Reeves, W. B. Mechanisms of cisplatin nephrotoxicity. Toxins 2, 2490–2518 (2010).
Blijham, G. et al. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur. J. Cancer 17, 433–441 (1981).
Mulder, P. O. et al. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur. J. Cancer Clin. Oncol. 24, 675–679 (1988).
Nichols, C. R. et al. Dose-intensive chemotherapy in refractory germ cell cancer — a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. Clin. Oncol. 7, 932–939 (1989).
Broun, E. R. et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. Intern. Med. 117, 124–128 (1992).
Einhorn, L. H. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer. Cancer Chemother. Pharmacol. 18, S45–S50 (1986).
Harstrick, A. et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J. Clin. Oncol. 9, 1549–1555 (1991).
Nichols, C. R. et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J. Clin. Oncol. 10, 558–563 (1992).
Ayash, L. J. et al. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant. 27, 939–947 (2001).
Einhorn, L. H. et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N. Engl. J. Med. 357, 340–348 (2007).
Motzer, R. J. et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 69, 550–556 (1992).
Pizzocaro, G. et al. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. Ann. Oncol. 3, 211–216 (1992).
Vaena, D. A., Abonour, R. & Einhorn, L. H. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J. Clin. Oncol. 21, 4100–4104 (2003).
Lorch, A. et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann. Oncol. 21, 820–825 (2010).
Siegert, W. et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J. Clin. Oncol. 12, 1223–1231 (1994).
Beyer, J. et al. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79, 161–168 (1997).
Beyer, J., Stenning, S., Gerl, A., Fossa, S. & Siegert, W. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann. Oncol. 13, 599–605 (2002).
Motzer, R. J. et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J. Clin. Oncol. 14, 1098–1105 (1996).
Rick, O. et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J. Clin. Oncol. 19, 81–88 (2001).
Motzer, R. J. et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J. Clin. Oncol. 18, 1173–1180 (2000).
Kondagunta, G. V. et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J. Clin. Oncol. 25, 85–90 (2007).
Feldman, D. R. et al. Phase I/II trial of paclitaxel with ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin (TI-TIC) with autologous stem cell reinfusion for salvage treatment of germ cell tumors. Clin. Genitourin. Cancer 13, 453–460 (2015).
Pico, J. L. et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann. Oncol. 16, 1152–1159 (2005).
Lorch, A. et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J. Clin. Oncol. 25, 2778–2784 (2007).
Lorch, A. et al. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. J. Urol. 184, 168–173 (2010).
Richardson, R. et al. Late relapse of germ cell tumors: detection and treatment outcomes. J. Clin. Oncol. 39, abstr 5007 (2021).
Feldman, D. R., Huddart, R., Hall, E., Beyer, J. & Powles, T. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J. Cancer 2, 374–377 (2011).
Spiess, P. E. et al. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer 110, 2700–2708 (2007).
Oldenburg, J. et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 362–375 (2022).
Gilligan, T. et al. Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 17, 1529–1554 (2019).
Cary, C. et al. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation. Cancer 121, 4369–4375 (2015).
Miller, M. I. et al. Surgical management of patients with advanced germ cell tumors following salvage chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) experience. Urology 124, 174–178 (2019).
Anouti, B. et al. Maintenance oral etoposide (VP-16) after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors (mGCT). J. Clin. Oncol. 38, 5051–5051 (2020).
Ashkar, R. et al. Randomized phase 2 trial of maintenance oral etoposide or observation following high-dose chemotherapy for relapsed metastatic germ cell tumor. J. Clin. Oncol. 40, TPS429–TPS429 (2022).
Haugnes, H. S. et al. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncol. 51, 168–176 (2012).
Kawai, K. et al. Neutropenic colitis as a complication of high-dose chemotherapy for refractory testicular cancer. Jpn. J. Clin. Oncol. 28, 571–573 (1998).
Fergadis, E. et al. Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor. Anticancer Drugs 30, 205–208 (2019).
Boccadoro, M. et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 87, 846–850 (2002).
Kroger, N. et al. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann. Hematol. 76, 257–262 (1998).
Kobold, S. et al. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients. Bone Marrow Transplant. 46, 1053–1056 (2011).
Tomblyn, M. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transpl. 15, 1143–1238 (2009).
Jathavedam, A. et al. Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biol. Blood Marrow Transpl. 14, 595–600 (2008).
Beyer, J. et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J. Clin. Oncol. 14, 2638–2645 (1996).
Chovanec, M. et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann. Oncol. 28, 2670–2679 (2017).
Chovanec, M. et al. Late adverse effects and quality of life in survivors of testicular germ cell tumour. Nat. Rev. Urol. 18, 227–245 (2021).
Laguna, M. P. et al. EAU guidelines on testicular cancer. Edition presented at the EAU Annual Congress Amsterdam 2022 (EAU, 2022).
Loehrer, P. J. Sr et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann. Intern. Med. 109, 540–546 (1988).
Mead, G. M. et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br. J. Cancer 93, 178–184 (2005).
Kondagunta, G. V. et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol. 23, 6549–6555 (2005).
M.C. acknowledges funding from the Slovak Research and Development Agency under contract nos. APVV-15-0086, APVV-19-0411 and VEGA 1/0327/19.
The authors declare no competing interests.
Peer review information
Nature Reviews Urology thanks Anja Lorch, Christoph Oing and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Chovanec, M., Adra, N., Abu Zaid, M. et al. High-dose chemotherapy for relapsed testicular germ cell tumours. Nat Rev Urol (2022). https://doi.org/10.1038/s41585-022-00683-1